Pasithea Therapeutics (KTTA) Non-Current Assets (2021 - 2026)
Pasithea Therapeutics (KTTA) posted Non-Current Assets of $3.6 million for Q1 2026, down 4.17% sequentially from $3.8 million in Q4 2025, and down 57.54% YoY from $8.5 million in Q1 2025.
Pasithea Therapeutics (KTTA) Non-Current Assets (2021 - 2026) Analysis & Trends
Pasithea Therapeutics has reported Non-Current Assets for 6 years, with the latest figure at $3.6 million in Q1 2026.
- Quarterly Non-Current Assets fell 57.54% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.9 million (down 31.99% YoY) and the FY2025 annual result came in at $3.8 million, down 56.52% from the prior year.
- Non-Current Assets declined to $3.6 million in Q1 2026 per KTTA's latest filing, from $3.8 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $11.1 million in Q4 2022 and troughed at $128619.0 in Q1 2022.
- A 5-year average of $7.6 million and a median of $8.7 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2026: Non-Current Assets soared 59863.97% in 2022, then slumped 57.54% in 2026.
- Over 5 years, Non-Current Assets stood at $11.1 million in 2022, then declined by 15.12% to $9.4 million in 2023, then decreased by 7.73% to $8.7 million in 2024, then sank by 56.52% to $3.8 million in 2025, then retreated by 4.17% to $3.6 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $3.6 million, $3.8 million, and $8.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Pasithea Therapeutics | 16.97 Mn | 16.97 Mn | - | 3.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.62 Mn |
| Dec 31, 2025 | 3.78 Mn |
| Sep 30, 2025 | 8.10 Mn |
| Jun 30, 2025 | 8.37 Mn |
| Mar 31, 2025 | 8.53 Mn |
| Dec 31, 2024 | 8.70 Mn |
| Sep 30, 2024 | 8.86 Mn |
| Jun 30, 2024 | 9.02 Mn |
| Mar 31, 2024 | 9.22 Mn |
| Dec 31, 2023 | 9.42 Mn |
| Sep 30, 2023 | 9.89 Mn |
| Jun 30, 2023 | 10.11 Mn |
| Mar 31, 2023 | 10.93 Mn |
| Dec 31, 2022 | 11.10 Mn |
| Sep 30, 2022 | 5.14 Mn |
| Jun 30, 2022 | 4.41 Mn |
| Mar 31, 2022 | 128,619.00 |
| Dec 31, 2021 | 20,124.00 |
| Sep 30, 2021 | 8,570.00 |